This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pfizer Signs Experimental Drug Licensing Agreement With 3SBio
by Zacks Equity Research
Pfizer inks Experimental Drug Licensing Deal With China-based company 3SBio.
NVAX Stock Surges on Securing FDA Approval for COVID-19 Vaccine
by Zacks Equity Research
The FDA grants full approval to Novavax's protein-based COVID-19 vaccine after nearly a two-month delay, albeit with some new conditions.
PFE vs. MRK: Which Oncology Drug Giant is a Better Buy Now?
by Kinjel Shah
Both PFE and MRK have strong product and pipeline portfolios in oncology.
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
5 Low Price-to-Book Value Stocks to Buy in May
by Kinjel Shah
The P/B ratio helps to identify low-priced stocks with high growth prospects. CNC, CVS, PFE, STNE and SAN are some such stocks.
Zacks.com featured highlights StoneCo, Centene, CVS Health and Pfizer
by Zacks Equity Research
StoneCo, Centene, CVS Health and Pfizer have been highlighted in this Screen of The Week article.
PFE vs. LLY: Which Stock Is the Better Value Option?
by Zacks Equity Research
PFE vs. LLY: Which Stock Is the Better Value Option?
4 Value Picks to Ride the Market Rebound After US-China Trade Thaw
by Sumit Singh
Value investing is essentially about selecting stocks that are usually cheap but fundamentally sound. STNE, CNC, CVS & PFE boast a low P/CF ratio.
Should Value Investors Buy Pfizer (PFE) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
The Zacks Analyst Blog Highlights J&J, Eli Lilly, Pfizer, Merck, Amgen
by Zacks Equity Research
J&J, Eli Lilly, Pfizer, Merck, Amgen are included in this Analyst Blog.
US-China Talks Spark Optimism; Betting Markets See Recession Odds Drop
by Andrew Rocco
A surprising thaw in US-China trade relations sparked significant optimism on Wall Street Monday. This positive development, coupled with lower recession odds, sets up a bullish long-term outlook for investors.
Drug Stocks Recover as Trump's Order Proves Not as Bad as Feared
by Kinjel Shah
President Trump issues an executive order that will push drugmakers to offer prescription drugs to U.S. cash-pay consumers at lower prices.
Pharma Stocks Hit by Trump's Vow to Cut US Prescription Drug Costs
by Kinjel Shah
The price cuts would see that U.S. consumers pay the same amount as the nation that pays the lowest price for that drug.
Zacks.com featured highlights PCB, G-III Apparel, Gibraltar, Pfizer and Pampa Energia
by Zacks Equity Research
PCB, G-III Apparel, Gibraltar, Pfizer and Pampa Energia have been highlighted in this Screen of The Week article.
Zacks Market Edge Highlights: WHR, PFE, CVX, CC and DOW
by Zacks Equity Research
WHR, PFE, CVX, CC and DOW have been highlighted in this Market Edge article.
Are Your Mega-High Stock Dividends Safe?
by Tracey Ryniec
Tracey Ryniec, Zacks Senior Stock Strategist, and Bryan Hayes, editor of Zacks Income Investor newsletter, discuss 5 popular stocks with high dividend yields. Can the dividend be trusted?
Pfizer (PFE) Just Overtook the 20-Day Moving Average
by Zacks Equity Research
Good things could be on the horizon when a stock surpasses the 20-day simple moving average. How should investors react?
5 Low Price-to-Sales Stocks That Deserve a Place in Your Portfolio
by Rajani Lohia
The price-to-sales ratio is a convenient tool to gauge the value of stocks incurring losses or in an early development cycle. Stocks like PCB, GIII, ROCK, PFE and PAM hold promise.
A Look at Pharma ETFs After Strong Q1 Earnings
by Sweta Killa
Many pharma bigwigs reported solid results, with some beating on earnings or revenues or both.
Can Pfizer (PFE) Climb 25.14% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Pfizer (PFE) points to a 25.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Moderna Sharpens Pipeline Focus as COVID-19 Vaccine Demand Ebbs in Q1
by Zacks Equity Research
Moderna plans to launch 10 new marketed products over the next three years, aiming to diversify a revenue base, which is still heavily reliant on COVID-19 vaccine sales.
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Top Wide-Moat Stocks to Invest in for Long-Term Growth
by Anindya Barman
Investing in wide-moat stocks like PFE, ASML, LRCX and KO can be a strategy for long-term wealth creation due to their ability to deliver consistent returns.
Pfizer Stock Up 5% Following Q1 Results: Time to Buy, Sell or Hold?
by Kinjel Shah
Investors may stay invested in PFE stock to see how its new growth drivers perform.
Summit Therapeutics Q1 Loss Narrower Than Expected, Sales Nil
by Zacks Equity Research
SMMT's first-quarter earnings outpace estimates. The company also provides updates on its pipeline.